Teprotumumab treatment for dysthyroid optic neuropathy

All patients had CON improvement with teprotumumab, typically over a rapid time course, and the vast majority had CON resolution. Despite proptosis regression, nearly all patients remained CON-free at long-term follow-up. These results suggest that teprotumumab may be an effective treatment for dysthyroid optic neuropathy, especially for patients with mild CON.